Endocyte (ECYT) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street indexes rise as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Strategy stock jumps 7% as firm shifts to active capital management
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
May 10, 2017 8:00 AM EDTWEST LAFAYETTE, Ind., May 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2017, and provided a clinical and pipeline update.
We look forward to providing safety and efficacy updates for our clinical trials of both EC1169 and EC1456 at the Annual Meeting of the American Society of Clinical Oncology (ASCO) next month, said Mike Sherman, president and CEO at Endocyte. In addition, we continue to discover... More
